CL2017002846A1 - Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t. - Google Patents
Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.Info
- Publication number
- CL2017002846A1 CL2017002846A1 CL2017002846A CL2017002846A CL2017002846A1 CL 2017002846 A1 CL2017002846 A1 CL 2017002846A1 CL 2017002846 A CL2017002846 A CL 2017002846A CL 2017002846 A CL2017002846 A CL 2017002846A CL 2017002846 A1 CL2017002846 A1 CL 2017002846A1
- Authority
- CL
- Chile
- Prior art keywords
- epstein
- treatment
- barr virus
- methods
- ebv
- Prior art date
Links
- 241000701044 Human gammaherpesvirus 4 Species 0.000 title abstract 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002659 cell therapy Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 238000009096 combination chemotherapy Methods 0.000 abstract 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160549P | 2015-05-12 | 2015-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002846A1 true CL2017002846A1 (es) | 2018-05-25 |
Family
ID=56027234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002846A CL2017002846A1 (es) | 2015-05-12 | 2017-11-10 | Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10568908B2 (OSRAM) |
| EP (1) | EP3294304B1 (OSRAM) |
| JP (2) | JP7284556B2 (OSRAM) |
| KR (1) | KR102666781B1 (OSRAM) |
| CN (1) | CN107835690A (OSRAM) |
| AR (1) | AR104598A1 (OSRAM) |
| AU (1) | AU2016262484B2 (OSRAM) |
| BR (1) | BR112017024431B1 (OSRAM) |
| CA (1) | CA2984178C (OSRAM) |
| CL (1) | CL2017002846A1 (OSRAM) |
| FR (1) | FR23C1025I2 (OSRAM) |
| IL (1) | IL255581B (OSRAM) |
| MX (1) | MX386334B (OSRAM) |
| NZ (1) | NZ736675A (OSRAM) |
| PH (1) | PH12017501993A1 (OSRAM) |
| RU (1) | RU2720245C2 (OSRAM) |
| WO (1) | WO2016183153A1 (OSRAM) |
| ZA (1) | ZA201707335B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017203356A1 (en) | 2016-05-25 | 2017-11-30 | The Council Of The Queensland Institute Of Medical Research | Methods of immunotherapy |
| JP7002769B2 (ja) * | 2016-09-16 | 2022-02-04 | ベイラー カレッジ オブ メディスン | ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム |
| AU2018355145A1 (en) | 2017-10-23 | 2020-04-30 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| CN108220237B (zh) * | 2017-12-20 | 2020-11-06 | 中国科学院遗传与发育生物学研究所 | 一种人的nk/t细胞系 |
| US20200350049A1 (en) * | 2018-01-08 | 2020-11-05 | Atara Biotherapeutics, Inc. | Systems and methods for distributing cell therapies |
| EP3765602A1 (en) | 2018-03-14 | 2021-01-20 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
| KR20220092905A (ko) * | 2019-10-23 | 2022-07-04 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 입양 면역요법 |
| CN118256604B (zh) * | 2024-04-16 | 2024-11-19 | 华中科技大学 | 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO784197A0 (en) * | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| JP4824389B2 (ja) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| RU2506311C2 (ru) | 2008-10-30 | 2014-02-10 | Йеда Рисёрч Энд Девелопмент Ко. Лтд. | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний |
| US20140086888A1 (en) | 2010-09-01 | 2014-03-27 | Helen E. Heslop | Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc) |
| BR112014027957A8 (pt) * | 2012-05-08 | 2018-01-16 | Univ Johns Hopkins | métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer" |
| CA2889064A1 (en) * | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| CN105848484A (zh) * | 2013-10-25 | 2016-08-10 | 得克萨斯州大学系统董事会 | 用于免疫治疗的多克隆γδ T细胞 |
| TWI673365B (zh) * | 2014-11-05 | 2019-10-01 | 美國紀念斯隆 凱特琳癌症中心 | 選擇用於過繼性細胞療法之ｔ細胞株及其供體之方法 |
| WO2017003763A1 (en) * | 2015-06-27 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Methods of treating glioblastoma multiforme by t cell therapy |
-
2016
- 2016-05-11 MX MX2017014257A patent/MX386334B/es unknown
- 2016-05-11 AU AU2016262484A patent/AU2016262484B2/en active Active
- 2016-05-11 CA CA2984178A patent/CA2984178C/en active Active
- 2016-05-11 CN CN201680039509.4A patent/CN107835690A/zh active Pending
- 2016-05-11 KR KR1020177034692A patent/KR102666781B1/ko active Active
- 2016-05-11 RU RU2017143151A patent/RU2720245C2/ru active
- 2016-05-11 US US15/572,557 patent/US10568908B2/en active Active
- 2016-05-11 WO PCT/US2016/031784 patent/WO2016183153A1/en not_active Ceased
- 2016-05-11 EP EP16724230.4A patent/EP3294304B1/en active Active
- 2016-05-11 AR ARP160101364A patent/AR104598A1/es unknown
- 2016-05-11 NZ NZ736675A patent/NZ736675A/en unknown
- 2016-05-11 JP JP2017559029A patent/JP7284556B2/ja active Active
- 2016-05-11 BR BR112017024431-4A patent/BR112017024431B1/pt active IP Right Grant
-
2017
- 2017-10-27 ZA ZA2017/07335A patent/ZA201707335B/en unknown
- 2017-11-02 PH PH12017501993A patent/PH12017501993A1/en unknown
- 2017-11-09 IL IL255581A patent/IL255581B/en active IP Right Grant
- 2017-11-10 CL CL2017002846A patent/CL2017002846A1/es unknown
-
2021
- 2021-04-19 JP JP2021070234A patent/JP2021119154A/ja active Pending
-
2023
- 2023-06-14 FR FR23C1025C patent/FR23C1025I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2984178A1 (en) | 2016-11-17 |
| KR102666781B1 (ko) | 2024-05-20 |
| US10568908B2 (en) | 2020-02-25 |
| AR104598A1 (es) | 2017-08-02 |
| BR112017024431A2 (pt) | 2018-07-24 |
| RU2017143151A (ru) | 2019-06-13 |
| EP3294304A1 (en) | 2018-03-21 |
| AU2016262484B2 (en) | 2021-10-21 |
| MX386334B (es) | 2025-03-18 |
| CA2984178C (en) | 2023-10-31 |
| RU2017143151A3 (OSRAM) | 2019-10-29 |
| JP7284556B2 (ja) | 2023-05-31 |
| CN107835690A (zh) | 2018-03-23 |
| FR23C1025I2 (fr) | 2025-04-18 |
| AU2016262484A1 (en) | 2018-01-04 |
| IL255581B (en) | 2021-03-25 |
| ZA201707335B (en) | 2021-02-24 |
| RU2720245C2 (ru) | 2020-04-28 |
| PH12017501993A1 (en) | 2018-03-26 |
| HK1244697A1 (en) | 2018-08-17 |
| FR23C1025I1 (fr) | 2023-07-21 |
| KR20180003575A (ko) | 2018-01-09 |
| US20180125891A1 (en) | 2018-05-10 |
| NZ736675A (en) | 2023-03-31 |
| JP2018520095A (ja) | 2018-07-26 |
| MX2017014257A (es) | 2018-04-20 |
| EP3294304B1 (en) | 2020-01-29 |
| BR112017024431B1 (pt) | 2021-10-13 |
| WO2016183153A1 (en) | 2016-11-17 |
| IL255581A (en) | 2018-01-31 |
| JP2021119154A (ja) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017014257A (es) | Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t. | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
| ECSP17077930A (es) | Métodos y kits para tratar la depresión | |
| BR112017002332A2 (pt) | terapia de combinação para o tratamento de um paramixovírus | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2015011296A (es) | Dispositivo foto-terapeutico, metodo y uso. | |
| MX376190B (es) | PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO. | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| BR112015006055A2 (pt) | composições e métodos para o tratamento e prevenção de lesão tecidual e doença | |
| NI201800039A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| ECSP17059323A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| MX2018014610A (es) | Uso de un anticuerpo anti proteina de muerte programada 1 (pd-1) en combinacion con un anticuerpo anti cumulo de diferenciacion 3d (cd30) en el tratamiento del linfoma. | |
| NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
| UY36518A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| MX2014011855A (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides. | |
| MX2017015292A (es) | Composicion para tratar lesiones cerebrales. | |
| BR112018067967A2 (pt) | tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| BR112021021787A2 (pt) | Terapias de combinação | |
| CL2017001407A1 (es) | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson | |
| EA201401352A1 (ru) | Вакцина против вируса шмалленберга (sbv), способы ее получения и применения | |
| AR105142A1 (es) | Métodos de tratamiento del glioblastoma multiforme con terapia de células t |